Optimal Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Optimal Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1.45M	Buy	18,768 +35	+0.2%	+$2.76K	0.18%	186
2021 Q2	$1.56M	Hold	18,733	–	–	0.19%	186
2021 Q1	$1.42M	Buy	18,733 +12,800	+216%	+$1.05M	0.18%	190
2020 Q4	$520K	Hold	5,933	–	–	0.07%	331
2020 Q3	$451K	Buy	+5,933	New	+$600K	0.07%	349

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Optimal Asset Management's BMRN Position: Q3 2021 in Review

Optimal Asset Management increased its BioMarin Pharmaceuticals (BMRN) stake by 0.19% in Q3 2021, buying an estimated $2.76K and bringing the position to 18,768 shares worth $1.45M. The position accounts for 0.18% of the portfolio, ranked #186.

Optimal Asset Management first reported a position in BMRN in Q3 2020 and has held it in 5 quarters since. The position peaked at $1.56M in Q2 2021. 511 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

Optimal Asset Management held 18,768 shares of BioMarin Pharmaceuticals worth $1.45M as of Q3 2021.
Optimal Asset Management bought 35 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $2.76K.
BioMarin Pharmaceuticals made up 0.18% of Optimal Asset Management's portfolio in Q3 2021, its #186 holding.
Optimal Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2020 and has held it in 5 quarters since.
Optimal Asset Management's BioMarin Pharmaceuticals position peaked at $1.56M in Q2 2021.
511 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Optimal Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.